If the science is as good as seen in the lab, then a...

If the science is as good as seen in the lab, then a 'breakthrough approval' will land in IMU lap as soon as the necessary in-human trial data is presented to the FDA. Once that is achieved, BP or no BP, it won't matter anymore. And I believe that is the point Team IMU is targeting. At that point in time, it is a matter of which BP will blink first or be left behind.

So really, patience is the key now. We are already so near to the pointy end. A deal now would be less desirable because IMU won't have any haggling power. But if a deal is being negotiated after an FDA breakthrough approval is achieved, then it is a matter of 'if you don't want it, NEXT!' because there will be a queue of BP waiting to sign up. Especially given all indications from management that they are VERY confident of getting a fast-track breakthrough approval. And if that is their belief, then they should act accordingly.

At end of day, I trust IMU management knows exactly what is in play here. Naturally only time will tell. But I am willing to wait till significant Vaxinia data is out. At least with that, IMU will be in a better negotiating position.